Entra Health Systems Makes News Strides in Diabetes Management

PRLog (Press Release) - Mar 25, 2009 -
California-based medical technology provider Entra Health Systems (EHS) announced today that it has chosen Sunderland in Northeast England for its base of operations in Europe.

“Technologies that are common in all walks of life - mobile phones, Bluetooth, communications, automation - are underutilized in healthcare.”  reads Entra Health System’s mission statement. To this end, EHS has created MyGlucoHealth, the world’s first FDA-cleared, Bluetooth-enabled glucose meter.  MyGlucoHealth will allow patients to wirelessly transmit blood glucose test results to a secure diabetes management portal online.  

With meters requiring the smallest blood sample on the market (0.3 microliters) and providing results within 3 seconds, diabetic patients now have an easier and quicker way to check and report their results.  The Bluetooth-enabled devices also gives patients a central location to record and track test results, while simultaneously providing physicians with ongoing chart data.  By helping healthcare providers and patients to work together, EHS wants to ensure that patients have access to appropriate care, support, and education to help them manage their condition and avoid serious health complications.

The potential to improve so many patients’ quality of life is one reason why EHS is choosing to launch MyGlucoHealth in the UK.  With 2.3 million of the 171 million people living with diabetes, the UK offers EHS access to the world’s single largest patient pool. EHS chose Sunderland, in particular, because North England is home to world-class research facilities, centers of excellence and companies in the life science, biotechnology and medical IT sectors.  The National Health Service (NHS), the UK’s publicly funded healthcare system, is also located in the region.

NHS provides significant partnership opportunities for the company. “The NHS is spending approximately $30k a year on a non-compliant patient versus $800 for a compliant patient.  Our technology will lower costs for both the patient and health systems, and improve the quality of life. EHS’s goals and philosophy is synergistic with NHS’.” affirms Rick Storbridge, CEO, Entra Health Systems.

Acting as catalyst and liaison, the North England Inward Investment Agency was an essential partner in introducing EHS to the people at NHS, Sean Croson, VP, North England Inward Investment Agency states, “North England’s legacy of innovation and collaborative environment are a great fit for companies like EHS. They represent a company with vision and purpose. We are delighted to have assisted them to improve people’s lives.”

“The move to Sunderland made sense,” Adds John Hendel, Chairman Entra Health Systems, “The talent, culture, and resources located in North England will accommodate our company’s growth and ambitious business objectives. North England Inward Investment Agency has been instrumental in the expansion process and they held our hands in dealing with everything from taxes to grants to bank referrals. They also facilitated our partnership with NHS.  We could not have done this without them.”

EHS will launch MyGlucoHealth in the UK, followed by Europe and North America.

About the Entra Health Systems (EHS)
Entra Health Systems applies technology to improve healthcare management. Our current business focuses are Diabetes Management, Marketing of Healthcare Intellectual Property, and Automating Patient Administration. We have operations in North America and Europe. For more information, please visit www.entrahealthsystems.com